How CuraYou’s ProWave Deep Healing Pad™ Applies Red and Infrared Light Therapy for Fibromyalgia

What the Research Requires

How Red and Infrared Light Therapy Address Fibromyalgia

Fibromyalgia disrupts multiple biological systems at once. Cellular energy production is impaired, with energy compound concentrations significantly lower in fibromyalgia muscle tissue (Gerdle et al., 2020) and CoQ10 levels in blood cells running at roughly 40–50% of normal (Cordero et al., 2010). Inflammation markers are significantly elevated (O'Mahony et al., 2021). The body's built-in pain-dampening system is measurably impaired (O'Brien et al., 2018). And nearly half of patients show evidence of small fiber pathology in the smallest nerve fibers (Grayston et al., 2019).

Red light therapy (photobiomodulation) addresses these disrupted systems by restoring cellular energy production in compromised tissue through direct stimulation of a key mitochondrial enzyme (cytochrome c oxidase), reducing the inflammatory signaling that amplifies pain and tissue dysfunction, counteracting the oxidative stress documented in fibromyalgia skin biopsies (Sánchez-Domínguez et al., 2015), and modulating pain processing at both peripheral and central nervous system levels. Near-infrared light penetrates deeper into muscle, joint, and nerve tissue, reaching the structures where fibromyalgia pain originates. Together, the two wavelength ranges address the condition at multiple tissue depths and through multiple biological pathways. The clinical evidence behind these mechanisms includes a meta-analysis of 9 RCTs with 325 patients showing large, statistically significant improvements across pain (SMD 1.18), physical function (SMD 1.16), fatigue (SMD 1.40), depression (SMD 1.46), and anxiety (SMD 1.46) — all exceeding the threshold for a large clinical effect. A 2025 umbrella review of 204 RCTs across all health conditions rated the evidence for photobiomodulation's effect on fibromyalgia fatigue at moderate certainty, the highest tier achieved in the analysis, and described fibromyalgia as among the conditions with the strongest evidentiary support.

Wavelength, Dosimetry, and Protocol Parameters

For any device to deliver these benefits, the research defines specific requirements. Red light wavelengths in the 630–670nm range target the mitochondrial enzyme (cytochrome c oxidase) that drives the cellular energy response. Foundational research identified two distinct absorption peaks for this enzyme: one in the red range (~660nm) and one in the near-infrared range (~830nm) (Wong-Riley et al., 2005). Near-infrared wavelengths between 808 and 905nm penetrate deeper into biological tissue because, within the optical window of approximately 650–950nm, longer wavelengths scatter less and are absorbed less by surface tissue layers (Ash et al., 2017). The largest fibromyalgia RCT (Silva et al., 2018) delivered 39.3 J per tender point site across 11 body locations using a multi-wavelength device combining a 905nm super-pulsed laser with 640nm red LEDs and 875nm infrared LEDs. The whole-body trials used 660nm red and 850nm near-infrared at 25.2 J/cm² over 20-minute sessions, 3 times per week for 4 weeks (Navarro-Ledesma et al., 2022).

The strongest clinical trial results came from treatment protocols running 2–3 sessions per week over 4–12 weeks, with measurable improvements emerging within the first 2–4 weeks and benefits building progressively through the treatment course. A triple-blinded RCT with 6-month follow-up found that quality of life improvements persisted at every assessment point through six months after treatment ended — the longest follow-up data in the fibromyalgia photobiomodulation literature. The therapy has shown no serious adverse events across 17 studies and 857 participants, and both the 2019 Yeh meta-analysis and the 2026 Ferreira systematic review confirmed safety at the studied parameters. For the complete safety evidence, see Photobiomodulation Safety for Fibromyalgia. But effectiveness depends on delivering the right wavelengths at sufficient power density with consistent treatment frequency — underpowered devices or inconsistent use fail to replicate what the clinical trials achieved.

Why the Cura ProWave Deep Healing Pad™ Uses LEDs Instead of Lasers

Most of the clinical evidence for photobiomodulation in fibromyalgia comes from professional-grade laser devices or laser/LED cluster probes used in rehabilitation clinics. If the strongest evidence base uses lasers, why does the Cura ProWave Deep Healing Pad™ use LEDs?

The Biology Does Not Require a Laser

The cellular mechanisms of photobiomodulation are wavelength-dependent, not device-dependent. A photon at a given wavelength triggers the same mitochondrial response regardless of whether it originates from a laser or an LED. Hamblin (2017), in a widely cited review in AIMS Biophysics, stated that all studies comparing lasers to equivalent LED sources at similar wavelength and power density have found essentially no difference between them, and that LEDs work equally well as lasers for photobiomodulation. Heiskanen & Hamblin (2018), out of Massachusetts General Hospital and Harvard, concluded that photobiomodulation does not appear to depend on lasers or coherence, and that LED therapy appears similarly effective for superficial and moderate-depth tissue applications at matched wavelength and dose. That equivalence is established in controlled comparisons where wavelength and energy density are precisely matched; translating it from lab conditions to a consumer device introduces variables (tissue contact angle, distance from target tissue, session-to-session positioning) that the comparison studies do not isolate, which is why device engineering and protocol design matter as much as the photon source. The 2025 systematic review of 17 fibromyalgia studies (Martín Pérez et al.) confirmed the clinical translation: positive outcomes were found across laser, LED, and combined devices. For the complete analysis, see LED vs. Laser Therapy for Fibromyalgia.

Lasers Carry Safety Risks Unsuitable for Home Use

Clinical lasers used in the fibromyalgia trials are Class 3B or higher medical devices that can cause eye damage upon direct or reflected exposure and require trained operators, controlled environments, and protective eyewear. LED-based devices at the irradiance levels used for photobiomodulation operate within safe limits for unsupervised home use, eliminating the risk of eye injury and removing the need for specialized training. The Cura ProWave Deep Healing Pad™'s medical-grade construction with 0 V/m EMF output and neoprene materials means no risk of burns or electromagnetic interference, a safety margin that clinical laser devices cannot offer outside a supervised setting.

Broader Coverage Is an Advantage, Not a Limitation

Lasers focus energy on a small area; LEDs distribute it across a broader surface. For fibromyalgia, where pain is widespread across multiple body regions, the broader delivery is the better match to the clinical problem. Clinical laser protocols required a therapist to apply light point by point across tender point locations. The Silva et al. (2018) trial treated 11 separate sites per session. Point-by-point application introduces variability in coverage and energy delivery even with trained operators. The Cura ProWave Deep Healing Pad™'s 18" × 8" treatment surface with 360 LEDs covers large body areas (neck and shoulders, lower back, hips, thighs) in a single placement, delivering consistent energy across the full treatment zone without gaps or missed areas. For a condition defined by widespread, multi-site pain, area coverage matters.

LED Enables Daily Home Use for a Chronic Condition

Fibromyalgia is a chronic condition requiring sustained, consistent treatment. Clinical laser protocols required patients to visit a rehabilitation clinic for each session, administered by trained personnel with handheld probe application across multiple tender points. For someone already managing fatigue, pain, and the logistical demands of a chronic illness, 2–3 clinic visits per week for 10–12 weeks is often impractical. An LED pad device enables daily home treatment without requiring a clinic visit, a second person, or specialized training, matching the treatment consistency the research identifies as the most important variable in achieving results.

How the Cura ProWave Deep Healing Pad™ Delivers PBM for Fibromyalgia

Wavelengths

The Cura ProWave Deep Healing Pad™ is built around 360 medical-grade LEDs: 240 near-infrared lights at 850nm and 120 red lights at 660nm. Both wavelengths fall within the therapeutic ranges documented in the fibromyalgia research and sit at the two primary absorption peaks of the mitochondrial enzyme (cytochrome c oxidase) documented as dysfunctional in fibromyalgia patients. The 660nm red light operates within the red absorption band (630–670nm) that clinical trials have consistently used for pain and inflammation reduction. The 850nm near-infrared light penetrates deeper into muscle, joint, and nerve tissue, the structures where fibromyalgia pain originates, reaching layers that red light alone cannot access as effectively. Computational modelling shows red light at 660nm reaches approximately 2.0mm penetration in skin tissue, while near-infrared at 850nm reaches approximately 2.4–2.5mm (Ash et al., 2017). In biological tissue where energy drops exponentially with depth, that difference changes which structures receive a therapeutic dose. The combination of both wavelengths matches the multi-wavelength approach used in the largest fibromyalgia RCT (Silva et al., 2018), which combined red LEDs, infrared LEDs, and a super-pulsed infrared laser.

Irradiance and Why Power Density Matters

The Cura ProWave Deep Healing Pad™ delivers 200 mW/cm² irradiance, one of the highest on the consumer market. What this specification means for tissue-level dosing involves a physical reality that applies to every photobiomodulation device, laser or LED: the surface energy measured at the device does not equal the energy that arrives at the target cells inside the tissue.

Even with direct skin contact, the light must still penetrate through skin and subcutaneous tissue to reach the muscles, joints, and nerves where fibromyalgia pain is generated. LED light scatters, reflects, and is absorbed as it passes through tissue, so the energy at depth is always less than the energy at the surface. Research has established that the majority of near-infrared energy deposits within the first 10mm, with residual energy reaching 15–20mm in some tissue types (Kaub & Schmitz, 2022). That depth is relevant to the tender point sites and muscle structures that define fibromyalgia's clinical presentation.

Higher irradiance at the surface means more energy reaches the target tissue at depth within a practical treatment time. At 200 mW/cm², the Cura ProWave Deep Healing Pad™ delivers sufficient energy density to achieve therapeutic doses at the tissue level during 15–20 minute sessions. A device with half the power density would require twice the treatment time to deliver the same dose, a difference that matters when fatigue is one of the patient's primary symptoms. Photobiomodulation follows a biphasic dose response, where both too little and too much energy reduce effectiveness (Hamblin, 2017); the Cura ProWave Deep Healing Pad™'s pre-set treatment modes are calibrated to deliver energy within the therapeutic window documented in the clinical literature.

Three Separate Treatment Modes

The device offers three operating modes: red light only (660nm), near-infrared light only (850nm), and combined red and infrared. Red light drives the superficial tissue response, i.e. cellular energy restoration, inflammation reduction, and pain modulation in skin and surface tissue layers. Near-infrared light reaches deeper muscle, joint, and nerve structures. The ability to run each wavelength independently or in combination means treatment can be adapted to the patient's specific situation: near-infrared mode when deep tissue pain is the priority, red light mode when surface-level inflammation and skin sensitivity are the primary concerns, and combined mode, the default for most fibromyalgia treatment, to address the condition at multiple tissue depths simultaneously.

Flexible Design for Widespread Pain

Fibromyalgia involves pain distributed across multiple body regions: neck, shoulders, upper and lower back, hips, thighs, arms. The Cura ProWave Deep Healing Pad™'s flexible neoprene construction and adjustable strap system allow the 18" × 8" pad to wrap around different body parts and conform to body contours, delivering consistent light contact across the treatment area. Clinical laser trials required repositioning a handheld probe across 11+ individual tender points per session. The Cura ProWave Deep Healing Pad™ covers large treatment zones in a single placement, and patients can reposition the pad between body areas within the same session to address multiple pain sites. The convenient strap system was designed specifically for older adults and ease of use, the population most affected by fibromyalgia.

Power Delivery and Consistency

The Cura ProWave Deep Healing Pad™ uses a large remote with big, easy-to-read controls rather than a small interface requiring dexterity or close vision. This design choice reflects who uses the device: people managing a chronic pain condition, often older adults, who need equipment that works without adding complexity to an already demanding daily routine. LED lifetime is rated at 50,000 hours, ensuring consistent power output across years of daily use without the degradation that affects lower-quality LED devices. Consistent power delivery throughout each session matters because photobiomodulation follows a biphasic dose response; inconsistent power output means inconsistent energy delivery, which means unpredictable biological response.

CuraYou's Recommended Protocol for Fibromyalgia

Based on the clinical research parameters and the physics of LED tissue delivery, CuraYou recommends daily 15–20 minute sessions applied to affected areas using the combined red and infrared mode. Treatment should begin consistently and continue daily, as the biological changes that drive symptom relief, i.e. restored cellular energy, reduced inflammation and modulated pain signaling are cumulative rather than immediate. The research shows measurable improvements emerging within 2–4 weeks, with benefits building progressively over 8–12 weeks of sustained use. The device's pre-set modes eliminate the need to calculate dosing parameters; the device applies the settings, the patient applies the device.

The Cura ProWave Deep Healing Pad™ comes with a cellular restoration protocol and progress tracking tools designed to build the daily treatment habit that the research identifies as the critical success factor. CuraYou also provides human support to help optimize therapy, not a chatbot, not an automated FAQ, but a team that answers questions about positioning, session timing, and protocol adjustments. For a condition where treatment consistency determines outcomes, that support structure is part of the clinical equation.

Where the Evidence Stands

The Cura ProWave Deep Healing Pad™ translates the clinical research behind red and infrared light therapy for fibromyalgia into a device built for daily home use. The 660nm red and 850nm near-infrared LEDs deliver wavelengths at the two primary absorption peaks of the mitochondrial enzyme documented as dysfunctional in fibromyalgia patients. The 200 mW/cm² irradiance, the highest on the consumer market, delivers clinically relevant energy doses within practical 15–20 minute sessions. Three separate modes allow targeted treatment based on whether superficial tissue, deep tissue, or both are the priority. The flexible wrap design covers large treatment areas across the multiple body regions where fibromyalgia pain concentrates, without requiring a clinic visit, a therapist, or point-by-point application.

The clinical evidence shows measurable improvements typically emerging within 2–4 weeks, with benefits building progressively over 8–12 weeks of consistent daily treatment. That timeline fits within CuraYou's 60-day risk-free return policy: enough time to complete a meaningful treatment course, evaluate whether the therapy is working, and decide whether to continue, or return the device for a full refund. The device is FDA Registered, ISO Certified, carries up to 3 years of product warranty, and can be purchased with your HSA or FSA card. Hundreds of verified customer reviews from people managing chronic pain confirm that the specifications translate into real-world results. You now have the device specifications, the clinical context, and the evidence boundaries to evaluate whether this approach fits your treatment plan. For the full scientific evidence, start with Red and Infrared Light Therapy for Fibromyalgia: What the Research Shows.